微创肺表面活性物质给药与气管插管后低峰压通气治疗中国早产儿呼吸窘迫综合征的随机对照试验方案
本研究为在中国14家三级新生儿重症监护病房开展的多中心随机对照试验,计划纳入600例胎龄250/7至316/7周、主要诊断为呼吸窘迫综合征的早产儿,随机分为微创肺表面活性物质给药(LISA)组或气管插管给药后低峰压通气(LPPSA)组,主要结局包括死亡、矫正胎龄36周时支气管肺发育不良严重程度及生后72小时内机械通气。
要点
- LISA与LPPSA的头对头比较尚缺乏稳健证据。
- 主要结局为死亡、BPD严重程度及72小时内机械通气。
- 次要结局包括呼吸支持时长、操作时间及并发症发生率。
核心结论
- 该试验旨在评估LISA与LPPSA两种肺表面活性物质给药方法对早产儿RDS的有效性、安全性及并发症的影响。
研究设计与样本
- 多中心随机对照试验,在中国14家三级新生儿重症监护病房开展,计划纳入600例胎龄250/7至316/7周、主要诊断为RDS的早产儿。
- 婴儿在具备肺表面活性物质治疗指征时随机分入LISA组或LPPSA组。
主要发现
- 原文为研究方案,尚未报告试验结果。
关键数值与推荐
- 主要结局包括死亡、矫正胎龄36周时支气管肺发育不良严重程度及生后72小时内机械通气。
- 次要结局包括机械通气天数、各种无创呼吸支持持续时间、吸入氧浓度、给药前后血氧饱和度及给药操作所需时间。
- 将评估早产儿视网膜病变、坏死性小肠结肠炎、脑室内出血、血流动力学显著的动脉导管未闭、气胸及给药后48小时内大量肺出血的发生率,以及每种技术的失败率。
临床怎么用
- 该试验结果可能为早产儿RDS肺表面活性物质给药方式的选择提供证据,但当前方案尚无结果,不能据此改变临床实践。
局限性
- 原文为研究方案,尚无结果数据,无法评估有效性及安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Less invasive surfactant administration (LISA) is a way of giving surfactant without endotracheal intubation and has shown to be promising in reducing the incidence of bronchopulmonary dysplasia (BPD) in preterm infants. However, the mechanism underlying its beneficial effect and variations in the technique of administration may prevent its widespread use. This trial aims to evaluate the effects of two methods of surfactant administration, LISA or endotracheal surfactant administration followed by low peak pressure (LPPSA) ventilation, in preterm infants with respiratory distress syndrome (RDS). METHODS: The LISA Or Low Peak Pressure trial is to be conducted in 14 tertiary neonatal intensive care units in China. A total of 600 preterm infants born with gestational age between 250/7 and 316/7 weeks and with a primary diagnosis of RDS will be involved in the study. Infants will be randomized to the LISA or LPPSA group when surfactant therapy is indicated. Primary outcomes include mortality, severity of bronchopulmonary dysplasia at 36 weeks of postmenstrual age (PMA), and mechanical ventilation (MV) in the first 72 h of life. Secondary outcomes include the days of MV, duration of all sorts of non-invasive respiratory support, fraction of inspired oxygen, oxygen saturation before and after surfactant administration, and time required to perform the procedure for surfactant administration. The incidence of comorbidities, including retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), hemodynamically significant patent ductus arteriosus (hsPDA), pneumothorax, and massive pulmonary hemorrhage within 48 h of surfactant administration, and the failure rates of each technique will be determined. DISCUSSION: Data from recent systematic review and meta-analysis have suggested a possible improvement in outcomes of preterm infants with RDS by the LISA technique. However, robust evidence is lacking. Why LISA plays a potential role in reducing respiratory morbidity, mainly BPD in preterm infants, remains unclear. The possible explanations are the active and uninterrupted delivery of continuous positive airway pressure during the LISA procedure and the avoidance of complications caused by intubation and relatively high pressure/volume ventilation following surfactant administration. We hypothesized that LISA's effectiveness lies mainly in avoiding relatively high-pressure positive ventilation immediately following surfactant administration. Thus, this multicenter randomized controlled trial will focus on issues of endotracheal intubation and the pressure/volume used during conventional surfactant administration. The effectiveness, safety and comorbidities of preterm infants following LISA or LPPSA will be evaluated. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1900020970. Registered on 23 January 2019.
引用
- Zhu J, Bao Y, Du L, et al. Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial. Trials. 2020. PMID: 32527290. doi:10.1186/s13063-020-04390-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。